echemi logo
web-logo
slogan
homepage
Product
  • Product
  • Supplier
  • Inquiry

    My ECHEMI

    EN

    Home > Medical News > Medical Research Articles > BeiGene Announces that Baiyueze(R) (zanubrutinib) has been accepted for marketing authorization by the European Medicines Agency for the treatment of chronic lymphocytic leukemia and marginal zone lymphoma

    BeiGene Announces that Baiyueze(R) (zanubrutinib) has been accepted for marketing authorization by the European Medicines Agency for the treatment of chronic lymphocytic leukemia and marginal zone lymphoma

    • Last Update: 2022-05-02
    • Source: Internet
    • Author: User
    Tags

    ppg color year 2019

    what considered protein
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com